Trial Profile
ATLAS-INH: A Phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, with inhibitory antibodies to factor VIII or IX
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Fitusiran (Primary) ; Factor IX inhibitors; Factor VIII inhibitor bypassing fraction; Recombinant factor VIIa
- Indications Haemophilia A; Haemophilia B
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS-INH
- Sponsors Alnylam Pharmaceuticals; Sanofi Genzyme
- 12 Dec 2023 Results of pooled analysis from Phase 1 (NCT02035605), Phase 1/2 (NCT02554773) and Phase 3 studies (NCT03417102, NCT03417245, NCT03549871) in PwH A/B, with or without inhibitors, PopPK/PD model, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 10 Apr 2023 Results published in the Lancet.
- 04 Apr 2023 According to Sanofi Media Release, the company look forward to sharing additional data on fitusiran later this year.